Vaxxa AB (VAXXA) fair value: what the stock is really worth
We calculate from audited financials what Vaxxa AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Vaxxa AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range kr 0.2724 – kr 14.91 · fair‑value band kr 0.6120 – kr 1.09 · the kr 0.4150 price screens below the kr 0.8160 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Vaxxa AB operates an auction platform, vaxxa.se, which provides private individuals and companies to sell and buy used objects in vehicles, machinery, and construction industry. The company was formerly known as Augeo Group AB and changed its name to Vaxxa AB in July 2023. Vaxxa AB was incorporated in 2015 and is based in Stockholm, Sweden.
Stock analysis
Vaxxa AB (VAXXA) currently trades at kr 0.4150, while our model-based Fair Value estimate is kr 0.8160, implying the stock looks roughly 49.1% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of kr 0.9000 per share, and 6 of the 7 models we run sit above the kr 0.4150 price.
Bear case: the Asset-Based group reads lowest at kr 0.2300, and 1 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 0.6120 (bear) to kr 1.09 (bull), the price of kr 0.4150 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Technology sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Vaxxa AB reported revenue of 75.0M SEK in FY2025 versus 0 SEK in FY2022. Reported net income was −9.4M SEK in FY2025.
Key figures
Market cap 18.0M SEK (≈ $1.8M) · P/S ratio 0.21 · EPS (TTM) kr −0.2000 · Net margin −12.5% · Return on equity −49.5% · Return on assets (EBIT) −19.7% · Operating margin 0.0% · Revenue (TTM) 92.8M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −12% fair-value upside, at 97%, VAXXA screens cheaper than that median.
Fair Value models
Bear kr 0.6120Fair Value kr 0.8160Bull kr 1.09
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.7/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−20.2%
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 693 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+80% · Top 25%
Profitability
Return on assets−22% · Bottom 25%
Net margin (TTM)−9% · Below median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth51% · Top 25%
Valuation Multiplesvs Software - Application median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vaxxa AB Fair Value". https://www.fairvalue-calculator.com/stock/VAXXA
Frequently asked questions
Is Vaxxa AB (VAXXA) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of kr 0.8160 versus a price of kr 0.4150, about +97% upside (undervalued).
What is the fair value of VAXXA?
Our model-based fair value for Vaxxa AB is kr 0.8160 (as of Sep 13, 2026), built from audited fundamentals. The current price: kr 0.4150.
What is the quality score of VAXXA?
Vaxxa AB has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vaxxa AB (VAXXA)?
Our model-based price target is the fair value of kr 0.8160 (as of Sep 13, 2026) from 7 valuation models. Cautious scenario kr 0.6120, optimistic scenario kr 1.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Vaxxa AB stock forecast for 2026?
Our models put fair value at kr 0.8160, about +97% upside versus a price of kr 0.4150 (undervalued). Cautious scenario kr 0.6120, optimistic scenario kr 1.09. The calculation is refreshed regularly with new filings.
What is the revenue of Vaxxa AB (VAXXA)?
Vaxxa AB reported trailing-twelve-month revenue of about 92.8M SEK (latest available figure, as of Sep 13, 2026).
What growth is priced into Vaxxa AB (VAXXA)?
For today's price to be fair in a discounted-cash-flow model, Vaxxa AB would have to grow free cash flow by -20.2 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +16.9 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of VAXXA use?
Our models discount Vaxxa AB at 8.4 %: a base by market capitalisation (nano), damped by beta 0.53, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vaxxa AB that is -20.2 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Vaxxa AB (VAXXA) delivered so far?
Over the past 2 years revenue at Vaxxa AB grew +16.9 % a year. The price currently implies -20.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vaxxa AB (VAXXA) growing?
The median revenue growth in the sector is +3.4 % a year. That is the yardstick for the growth priced into Vaxxa AB (-20.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vaxxa AB (VAXXA)?
The free-cash-flow yield on the price is 13.49 %: that much free cash flow Vaxxa AB produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vaxxa AB (VAXXA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaxxa AB it is kr 0.8160 per share (as of Sep 13, 2026), against a price of kr 0.4150. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Vaxxa AB stock overvalued or undervalued in 2026?
As of Sep 13, 2026, VAXXA trades below its calculated fair value: price kr 0.4150, fair value kr 0.8160, a gap of about +97% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VAXXA?
No. The price is what the market pays today (kr 0.4150); the fair value is what the company's own numbers justify (kr 0.8160). For Vaxxa AB the two are kr 0.4010 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vaxxa AB worth?
The market values Vaxxa AB at about 18.0M SEK (market capitalisation, as of Sep 13, 2026). Per share that is kr 0.4150; our models calculate a fair value of kr 0.8160 per share.
What do the bullish and bearish scenarios say about VAXXA?
Our models span a range for Vaxxa AB: cautious scenario kr 0.6120, base kr 0.8160, optimistic kr 1.09 per share (as of Sep 13, 2026, price kr 0.4150). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vaxxa AB (VAXXA)?
Balance-sheet figures for Vaxxa AB (as of Sep 13, 2026): return on equity −49.5%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is VAXXA from its 52-week high?
Vaxxa AB trades at kr 0.4150, about 54% below its 52-week high of kr 0.9040 and 18% above the low of kr 0.3530 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.8160 is for.
Which stocks are comparable to Vaxxa AB?
From the same area (Technology) we also value SAP SE, Shopify Inc, Uber Technologies, Inc, Salesforce, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vaxxa AB stock attractive at the current price?
The data as of Sep 13, 2026: price kr 0.4150, calculated fair value kr 0.8160 (+97%), Quality Score 40/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VAXXA calculated?
We run Vaxxa AB through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.8160, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Vaxxa AB currently trades 97 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vaxxa AB (VAXXA)?
The closing price on Sep 15, 2026 was kr 0.4150. Our model-based fair value is kr 0.8160, about +97% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vaxxa AB right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (kr 0.6120). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Vaxxa AB
How large is the market capitalisation of Vaxxa AB (VAXXA)?
The market capitalisation of Vaxxa AB is 18.0M SEK (≈ $1.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vaxxa AB (VAXXA)?
The price-to-sales ratio of Vaxxa AB is 0.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vaxxa AB (VAXXA)?
Earnings per share at Vaxxa AB are kr −0.2000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vaxxa AB (VAXXA)?
The net margin of Vaxxa AB is −12.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vaxxa AB (VAXXA)?
The return on equity (ROE) of Vaxxa AB is −49.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vaxxa AB (VAXXA)?
On an EBIT basis the return on assets of Vaxxa AB is −19.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vaxxa AB (VAXXA)?
The operating margin of Vaxxa AB is 0.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vaxxa AB (VAXXA)?
Revenue at Vaxxa AB is growing +50.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Vaxxa AB in the live analysis
One click puts Vaxxa AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
